You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 202171 - 202180 of 207726 results
  1. Human Anti-WISP1 Antibodies for Treatment of Idiopathic Pulmonary Fbrosis

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): New anti-fibrotic drugs are needed to treat Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, chronically debilitating clinical syndrome with unknown etiology and a terminal outcome. IPF symptoms include persistent cough, progressive severe shortness of breath and decreased exercise capacity. Up to 200,000 Americans suffer from this disease with expect ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  2. Improved Oral P-selectin Blocker for Prophylactic Sickle Cell Disease Therapy

    SBC: VANGUARD THERAPEUTICS, INC.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Sickle cell disease (SCD) is a poorly treated debilitating condition for which we are developing a promising, new oral prophylactic therapy. A dire need exists for our drug, as millions of patients whohave inherited SCD world-wide, ~100,000 in the US, continue to suffer with episodic pain, disability, and premature death. Hydrox ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  3. Myocardial blood flow quantitation with the novel F-18 Flurpiridaz PET imaging tr

    SBC: SYNTERMED INCORPORATED            Topic: NHLBI

    Coronary artery disease continues to be a major contributor to the cause of death in the United States. The ability to diagnosis CAD in patients at an early stage has improved over the years resulting in reducing the mortality rate. In nuclear medicine/cardiology, the SPECT and PET myocardial perfusion imaging (MPI) methods and radiopharmaceuticals used clinically over the past 10 years have offer ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  4. Improving red blood cell transfusion through systems biology

    SBC: SINOPIA BIOSCIENCES INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Red blood cells (RBC) stored in approved additive solutions undergo a set of metabolic and physicochemical changes referred to as 'storage lesions' reducing the efficacy and safety of older transfused RBC units. Thoughthe consequences of the storage lesion are slowly becoming well documented, a major reason for delayed progress in developing new techn ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  5. Novel Inhaled Therapy for Idiopathic Pulmonary Fibrosis

    SBC: ANTEGRIN THERAPEUTICS, INC            Topic: NHLBI

    DESCRIPTION (provided by applicant): Idiopathic pulmonary fibrosis (IPF) is a deadly lung disease that affects an estimated 133,000 patients in the U.S. and more than 5 million worldwide. Median survival time after diagnosis is only 2-3 years, with a 5-year mortality rate exceeding 50%. IPF is the leading indication for lung transplant in most large treatment centers. The hallmark of the disease i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  6. Rho GTPase inhibitors for refrigerated platelet storage

    SBC: P2D, INC            Topic: NHLBI

    ABSTRACT The use of platelet transfusions has increased dramatically since 1980s, but a safe, long-term platelet storage method remains missing. Current practice has platelets stored at 20 to 24 C after preparation, which has a limited lifetime up to 5 days primarily due to concerns about bacterial contamination. Refrigerated storage reduces platelet life-span because it causes glycoprotein-Ib (GP ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  7. Depletion of iNKT Cells in the Treatment of Hypoxic Crises in Sickle Cell Mice

    SBC: NKT THERAPEUTICS, INC.            Topic: NHLBI

    There is a central role for iNKT cells in mediating inflammatory responses in sickle cell disease. NKT Therapeutics has developed a humanized monoclonal antibody (NKTT120) that can specifically mediate iNKT cell depletion by antibody and complement directed cellular cytotoxicity. We are currently engaged in a safety/PK Phase 1 study in stable sickle cell disease patients. Although the use of speci ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  8. Mobile multifunctional tool for monitoring and management of respiratory diseases

    SBC: TF HEALTH CORPORATION            Topic: NHLBI

    DESCRIPTION (provided by applicant): Mobile multifunctional tool for monitoring and management of respiratory diseases Chronic Obstructive Pulmonary Disease (COPD) and asthma affect millions of people worldwide. Because there is no permanent cure for thesediseases, efficient management of the patients over their entire lifetime are needed, which becomes increasingly difficult with the rapid rise i ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  9. Thromboresistant Small Diameter Tissue-Engineered Vascular Grafts

    SBC: HUMACYTE, INC.            Topic: NHLBI

    The overall goal of this Phase I SBIR application is to develop a non-cell-based means of inhibiting coagulation and platelet activation on engineered vascular grafts, so that small-diameter arterial grafts may be available off the shelf. This arterial graft will consist of human engineered tissue that is decellularized and coated with a novel, covalently-bound layer that mimics aspects of the e ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
  10. Mitigation of Reperfusion Injury During CPR to Improve Cerebral Recovery

    SBC: RESQSYSTEMS, INC.            Topic: NHLBI

    Abstract On average, gt90% of patients who suffer from a cardiac arrest die. Nearly all die unexpectedly from this leading cause of death, in part, because the essential components of standard CPR (S-CPR): manual chest compressions at a rate of 100/min, 1to 1.5 inches in depth and positive pressure ventilations, are an inherently inefficient process, providing less than 25% of normal blood flow to ...

    SBIR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government